DelveInsight's “Persistent Corneal Epithelial Defects Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Persistent Corneal Epithelial Defects ...

Please provide your email address to receive an email when new articles are posted on . The approval and commercialization of Oxervate (cenegermin-bkbj, Dompé) in the United States has improved our ...

Please provide your email address to receive an email when new articles are posted on . All eyes that received a single-layer graft and a 24-hour pressure patch showed complete healing. A three-layer ...

Credit: Thinkstock. KPI-012 is a topically dosed ophthalmic therapy designed using the Company's human mesenchymal stem cell secretome platform. The Food and Drug Administration (FDA) has granted Fast ...

Dublin, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The "Persistent Epithelial Defect Market - A Global and Regional Analysis: Focus on End User and Region, 2025-2035" has been added to ResearchAndMarkets.com's ...

There were 35 eyes of 33 patients, with a mean age of 68.2±19.5 years (range: 17–99 years). There were 25 men and 8 women. Median follow-up was 110 days (mean: 164.6 days; range: 30–960 days). The ...

A 68-year-old insulin-dependent diabetic male patient presented with progressive pain, redness, photophobia, tearing, and decreased vision of 1-month duration in his left eye. He had history of ...

Five cases are presented to emphasize the fact that chronic use of topical anesthetics on the eye can lead to severe keratitis and even permanent reduction of visual acuity. These reactions can be ...

Kala Pharmaceuticals (KALA) is a great speculative biotech play to look into. The reason why I state that is because it received IND clearance from the FDA to initiate a phase 2b study, using its ...